Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination

por Alexander, Neal D. E.
Publicado 2015

The genomic evolution of human prostate cancer

por Mitchell, T, Neal, D E
Publicado 2015

Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder.

por Clifford, S. C., Neal, D. E., Lunec, J.
Publicado 1996

Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor.

por Mellon, J. K., Cook, S., Chambers, P., Neal, D. E.
Publicado 1996

Robotic-assisted laparoscopic prostatectomy

por Sharma, N L, Shah, N C, Neal, D E
Publicado 2009

Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay.

por Clifford, S. C., Thomas, D. J., Neal, D. E., Lunec, J.
Publicado 1994

Pathogenesis of prostate cancer and hormone refractory prostate cancer

por Girling, J. S., Whitaker, H. C., Mills, I. G., Neal, D. E.
Publicado 2007

Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study.

por Naguib, R. N., Robinson, M. C., Neal, D. E., Hamdy, F. C.
Publicado 1998

Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer

por Gnanapragasam, V J, Leung, H Y, Pulimood, A S, Neal, D E, Robson, C N
Publicado 2001

Expression of c-erbB-2 protein product in bladder cancer.

por Wright, C., Mellon, K., Neal, D. E., Johnston, P., Corbett, I. P., Horne, C. H.
Publicado 1990

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associat...

por Abdel-Fattah, R., Challen, C., Griffiths, T. R., Robinson, M. C., Neal, D. E., Lunec, J.
Publicado 1998

Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer

por West, A F, O'Donnell, M, Charlton, R G, Neal, D E, Leung, H Y
Publicado 2001

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer

por Drake, M J, Robson, W, Mehta, P, Schofield, I, Neal, D E, Leung, H Y
Publicado 2003

Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67

por Tut, V M, Braithwaite, K L, Angus, B, Neal, D E, Lunec, J, Mellon, J K
Publicado 2001

UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer

por Unoki, M, Kelly, J D, Neal, D E, Ponder, B A J, Nakamura, Y, Hamamoto, R
Publicado 2009

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

por Wright, C., Mellon, K., Johnston, P., Lane, D. P., Harris, A. L., Horne, C. H., Neal, D. E.
Publicado 1991

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

por Pashayan, N, Duffy, S W, Pharoah, P, Greenberg, D, Donovan, J, Martin, R M, Hamdy, F, Neal, D E
Publicado 2009

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening

por Pashayan, N, Duffy, S W, Chowdhury, S, Dent, T, Burton, H, Neal, D E, Easton, D F, Eeles, R, Pharoah, P
Publicado 2011

Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.

por Autzen, P., Robson, C. N., Bjartell, A., Malcolm, A. J., Johnson, M. I., Neal, D. E., Hamdy, F. C.
Publicado 1998

Evaluation of epidermal growth factor receptors in bladder tumours.

por Berger, M. S., Greenfield, C., Gullick, W. J., Haley, J., Downward, J., Neal, D. E., Harris, A. L., Waterfield, M. D.
Publicado 1987